Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum- sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study

Article English OPEN
van de laar, Rafli; Zusterzeel, Petra LM; Van Gorp, Toon; Buist, Marrije R; van Driel, Willemien J; Gaarenstroom, Katja N; Arts, Henriette J. G.; van Huisseling, Johannes C. M.; Hermans, Ralph H. M.; Pijnenborg, Johanna M. A.; Schutter, Eltjo M. J.; Pelikan, Harold M. P.; Vollebergh, Jos H. A.; Engelen, Mirjam J. A.; IntHout, Joanna; Kruitwagen, Roy F. P. M.; Massuger, Leon F. A. G.;
  • Publisher: Springer Nature
  • Journal: BMC Cancer,volume 14,issue 1,pages22-22 (issn: 1471-2407, eissn: 1471-2407)
  • Publisher copyright policies & self-archiving
  • Related identifiers: doi: 10.1186/1471-2407-14-22, pmc: PMC3897943
  • Subject: Secondary cytoreductive surgery | Genetics | Ovarian cancer | CLINICAL-TRIALS | Study Protocol | Platinum-sensitive | Recurrent | Cancer Research | Oncology
    mesheuropmc: endocrine system diseases | female genital diseases and pregnancy complications

Background Improvement in treatment for patients with recurrent ovarian cancer is needed. Standard therapy in patients with platinum-sensitive recurrent ovarian cancer consists of platinum-based chemotherapy. Median overall survival is reported between 18 and 35 months.... View more
  • References (13)
    13 references, page 1 of 2

    1. Ledermann JA, Raja FA: Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer. Eur J Cancer 2011, 47:S104-S115.

    2. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, et al: Paclitaxel plus platinumbased chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361(9375):2099-2106.

    3. Pfisterer J, Vergote I, Du Bois A, Eisenhauer E: Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 2005, 15(Suppl 1):36-41.

    4. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR: OCEANS: a randomized, double-blind, placebocontrolled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012, 30(17):2039-2045.

    5. Bristow RE, Puri I, Chi DS: Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009, 112(1):265-274.

    6. Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schroder W, et al: Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006, 13(12):1702-1710.

    7. Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, et al: Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 2011, 21(2):289-295.

    8. Tian WJ, Chi DS, Sehouli J, Trope CG, Jiang R, Ayhan A, Cormio G, Xing Y, Breitbach GP, Braicu EI, et al: A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol 2012, 19(2):597-604.

    9. Woelber L, Jung S, Eulenburg C, Mueller V, Schwarz J, Jaenicke F, Mahner S: Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer. Eur J Surg Oncol 2010, 36(6):583-588.

    10. Galaal K, Naik R, Bristow RE, Patel A, Bryant A, Dickinson HO: Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev 2010, 6, CD007822.

  • Related Research Results (1)
  • Metrics
Share - Bookmark